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Abstract: Conjugated linoleic acid (CLA) is a group of geometrical and positional isomers of linoleic acid (C18:2, cis-9, cis-12). In
contrast to linoleic acid, double bonds in CLA are usually located at positions 9 and 11 or 10 and 12 and each double bond can be
either in the cis or trans configuration. Meat and dairy products from ruminant animals (such as milk, butter, yogurt and cheese)
are the principal natural sources of CLA in the human diet. Egg and meat products from poultry contain less CLA than meat from
ruminant animals (0.6 and 0.9 mg/g fat vs. 2.9 to 5.6 mg/g fat, respectively). Meat from turkeys contains much higher CLA relative
to meat from chickens. Dietary CLA has been shown to have potent anticarcinogenic and antiatherogenic effects in animal models.
CLA was also found to have a potent immune modulating activity characterized by increased blastogenesis and macrophage killing
ability. In addition to these biological properties, CLA was reported to reduce body fat content and increase lean body mass in pigs
and rodents. Because of these biological properties of CLA, recently there has been a lot of interest in enriching egg, meat and dairy
products for human consumption.
Key Words: Conjugated linoleic acid, anticarcinogenic, antiatherogenic, fat reducer, immune enhancer

Konjuge Linoleik Asitin Kimyasal Yap›s›, Kaynaklar› ve Biyolojik Özellikleri
Özet: Konjuge linoleik asit (CLA) esansiyel bir ya¤ asiti olan linoleik asitin (C18:2, cis-9, cis-12) pozisyonel ve yap›sal izomer guruplar›
için kullan›lan bir terimdir. Linoleik asitin yap›s›na k›yasla CLA içindeki konjuge olan çift ba¤lar, zincirde 9. karbon ve 11. karbon veya
10. karbon ve 12. karbonlarda yer alm›fllard›r. CLA’nin yap›s›nda her bir çift ba¤ cis veya trans konumunda yer alabilir. Ruminant
hayvanlardan elde edilen et ve süt ürünleri (örne¤in tereya¤, yo¤urt ve peynir) insanlar›n yiyeceklerinde bulunan do¤al CLA
kaynaklar›d›r. Kanatl›lardan elde edilen yumurta ve et (s›ras›yla yaklafl›k 0,6 ve 0,9 mg CLA/g ya¤), ruminantlardan elde edilen ete
k›yasla (2,9 ile 5,6 mg CLA/g ya¤) CLA bak›m›ndan zengin kaynaklar de¤ildir. Hindi eti tavuk etine k›yasla daha yüksek oranda CLA
içerir. CLA’nin biyolojik özelliklerinden dolay› CLA’e büyük ilgi görülmektedir. Diyetle al›nan CLA’nin hayvan modellerinde etkili
antikarsinojen etkiye sahip oldu¤u ve kalp-damar hastal›klar› riskini (antiatherojenik) düflürdü¤ü gösterilmifltir. CLA’nin ba¤›fl›kl›k
sisteminde blastogenezisi ve makrofajlar›n öldürme kabiliyetlerini art›rd›¤› da bulunmufltur. Bu biyolojik aktivitelere ek olarak CLA’nin
domuz ve kemiricilerin vücutlar›ndaki ya¤ oran›n› azaltt›¤› da rapor edilmifltir. Bu biyolojik özelliklerinden dolay›; yumurta, k›rm›z›
et ve süt ürünlerinin CLA ile zenginlefltirilmesi insan beslenmesi bak›m›ndan önem kazanm›flt›r.
Anahtar Sözcükler: Konjuge linoleik asit, antikarsinojenik, antiaterojenik, ya¤ düflürücü, ba¤›fl›kl›¤› art›r›c›

Introduction
Conjugated linoleic acid (CLA) is a mixture of
positional and geometrical isomers of linoleic acid (C18:2,
cis-9, cis-12), an essential fatty acid for human and
animals, and involves a double bond at positions 8 and
10, 9 and 11, and 10 and 12 or 11 and 13 (1). Each of
these positional conjugated diene isomers can occur in cistrans, trans-cis, cis-cis or trans-trans geometrical
configurations.
For over 50 years, CLA has been known to be present
in dairy products and other foods derived from ruminant
animals (2). Interest in CLA increased substantially

following the observation of anticarcinogenic effect in the
animal models fed cancer stimulating compounds (i.e. 7,
12-dimethylbenz[a]antracene or DMBA). In addition to
anticarcinogenic effects, CLA was also reported to inhibit
atherosclerotic lesions, to increase immune function, to
decrease body fat, and to increase lean body mass in
several animal models. Since CLA is a mixture of several
isomers, any isomer might have different activities or
work synergistically. Currently, c-9, t-11 CLA and t-10, c12 CLA isomers are the only isomers that have actually
been shown to exert physiological properties (Figure 1).
Meat and dairy products from ruminant animals are
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COOH C18:2 (c-9, c-12)

COOH C18:2 (c-9, t-11)

COOH C18:2 (c-9, c-12)
Figure 1. Structures of linoleic acid (top), c-9, t-11 CLA (middle) and t-10, c-12 CLA
isomer (bottom).

the principal sources of CLA in the human diet. The
concentration of CLA in cow’s milk is variable and ranges
from 2.4 to 21.8 mg of CLA/g of fat (3). The
concentration of CLA in milk is known to vary among
individuals and herds and between seasons. The greatest
concentration of CLA was found during grazing period of
animals. A total level of CLA in the human milk is lower
than the cow milk and ranges from 0.37% to 0.75% of
fat (4). The major CLA isomer in bovine (5) and human
(4) milk was reported to be the c-9, t-11 CLA isomer. In
meats and dairy products, the c-9, t-11 CLA isomer was
shown to be the major CLA isomer and accounts for 75%
and 90% of the conjugated dienes, respectively (2).
Biosynthesis of Conjugated Linoleic Acid
The major contributors to the formation of CLA in the
foods are due to heat treatment (6) and microbial
enzymatic reactions involving long chain fatty acids
(mainly linoleic or linolenic acids) in the rumen (7). In the
rumen, sequential reduction steps convert linoleic acid
(C18:2 c-9, c-12) to the c-9, t-11 CLA, then to vaccenic
acid (C18:1, t-11) and eventually to stearic acid (Figure
2) (8). CLA in the milk or meat from ruminant animals is
derived from either CLA escaping from complete rumen
biohydrogenation (9) or from absorbed C18:1, t-11,
which is acted on by stearoyl-CoA reductase and
converted to the c-9, t-11 CLA (7). Early studies showed
that the level of CLA in the milk and butter was positively
related to the intake of linoleic acid in diet (5).
Not only bacteria in the rumen, but also
microorganisms in the digestive system of nonruminant
animals (10) and humans (11) can synthesize CLA from
long chain fatty acids. CLA was reported to be generated
in the colon of conventional, but not in germ-free rats fed
diets containing free linoleic acid (10).
190

Enhancement of CLA in Animal Products
Since dietary CLA has some biological properties,
enhancing the CLA concentration of egg, milk and meat is
of interest. Compared to meat and dairy products from
ruminant animals, eggs and meat from poultry contain
far less CLA (2). Laying hens fed a diet supplemented with
5% CLA for 29 days had enriched levels of CLA in egg
yolks (12). However, dietary CLA was shown to cause
adverse effects on the quality of eggs stored at 4 °C for
10 weeks (13,14). CLA in low-fat diets increased the level
of saturated fatty acids (SFA) (mainly C16:0 and C18:0)
and decreased the levels of monounsaturated fatty acids
(MUFA) [mainly C16:1(n-7) and C18:1(n-9)] presumably
due to an inhibitory effect of the t-10, c-12 CLA isomer
on stearoyl-CoA desaturase enzyme. Enriching chicken
eggs with CLA is possible by feeding CLA in the presence
of any other fats (14). Chicken egg could be enriched 43fold higher with CLA compared to control when 2% CLA
and 4% canola oil were used together in chicken diet
(15).
Research has demonstrated means of enriching the
CLA content of animals and their products. A study
showed that the concentration of CLA in the milk could be
enhanced by the addition of sunflower oil (high in linoleic
acid) and linseed oil (high in linolenic acid) in ruminant
diets (16). Another study conducted in goat showed that
2% or 4% canola oil in the diet increased the levels of
CLA 2- and 3-fold, respectively, in the milk compared to
control (17). Others showed that feeding dairy cattle
marine algae caused a 7-fold increase in the level of CLA
in the milk compared to control (18).
The main isomers of CLA (i.e. c-9, t-11 CLA and t-10,
c-12 CLA isomers) were shown to be incorporated into
liver, heart, backfat, and omental fat of pigs fed CLA
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c-6, c-9, c-12
(gama linolenic acid)

c-9, c-12
(linolenic acid)

c-6, c-9, t-11
c-9, t-11
(conj. octadecatrienoic acid) (conj. octadecadienoic acid)
c-6, t-11
(octadecadienoic acid)

c-9, c-12, c-15
(alfa linolenic acid)

c-9, t-11, c-15
(conj. octadecatrienoic acid)
t-11, c-15
(octadecadienoic acid)

t-11
(vaccenic acid)

C18:0
(stearic acid)
Figure 2. Predominant pathways of biohydrogenation of unsaturated C18 fatty acids
(8).

mixture in a dose-dependent manner (19). The levels of
the c-9, t-11 and t-10, c-12 CLA isomers decreased at
similar rates in liver and fat pads when supplemental CLA
was withdrawn from diet (20). The t-10, c-12 CLA
isomer was reported to be cleared significantly faster
than the c-9, t-11 CLA isomer in the skeletal muscle (20).
It was suggested that the t-10, c-12 CLA isomer might be
metabolized more rapidly than the c-9, t-11 CLA isomer
(19), particularly in skeletal muscle (21).

cancer cells in severely compromised immunodeficient
(SCID) mice (27). This property of CLA is in sharp
contrast to the procancer activity associated with feeding
linoleic acid (28). A number of studies showed that
linoleic acid actually enhanced the development of
mammary tumors in rodents (29). Recently, it was
shown that linoleic acid increased prostate cancer (27).
Also, CLA was reported to inhibit the proliferation of
human malignant melanoma, colorectal and breast cancer
cells in in-vitro studies (30).

Biological Properties of CLA

An epidemiological study conducted in Finland showed
a significant inverse relation between milk consumption
and incidence of breast cancer in women in a 25-year
reporting period (31). Recently, CLA-enriched butterfat
was reported to alter mammary gland morphogenesis
and to reduce the risk of cancer in rats (32).

Anticarcinogenic Activities of CLA
The existence of CLA has been known for over 50
years. However, the recent interest in CLA began with the
isolation from hamburger meat as an anticarcinogenic
factor (22). Partially purified extracts from fried ground
beef was shown to contain mutagenic modulator activity
inhibiting the initiation of mouse epidermal carcinogenesis
by 7, 12-dimethylbenz[a]antracene (DMBA), a
procarcinogen (22). Then, this anticarcinogenic
compound was isolated and identified, and designated as
CLA (6).
In the 1990s, CLA was repeatedly shown to have
anticarcinogenic effects in animal models for stomach
neoplasia (23), mammary tumors (24), and skin
papillomas (25). It was found that as low as 0.05% level
of CLA was enough to significantly decrease the number
of induced mammary tumors in rodents (26). CLA was
shown to be effective in reducing the size and metastasis
of transplanted human breast cancer cells and prostate

Like other PUFA, CLA may modulate carcinogenesis by
mechanisms affecting the separate stages of cancer
development known as initiation, promotion, progression
and/or regression. However, the actual mechanism by
which CLA affects carcinogenesis has yet to be described.
A study suggested that CLA might act by antioxidant
mechanisms (23). Others suggested that CLA might act
by inhibiting nucleotide synthesis (30) or inhibiting both
DNA-adduct formation (33) and carcinogen activation, as
opposed to direct interaction with the procarcinogen,
scavenging of electrophiles or selective phase I
detoxification pathways (34). Some proposed that the
mechanism of tumor inhibition by dietary CLA might be
related to its ability to regulate lipoxygenase and
cyclooxygenase lipid mediators (35). Recently, it has been
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hypothesized that there might be more than one
mechanism by which CLA influences carcinogenesis (36).
B. Fat Reducing Activity of CLA
Generally, fatty acids containing trans double bonds
have a negative impact on lipid metabolism and depress
the amount of milk fat (37). While linoleic acid has two
double bonds with cis configuration (C18:2 c-9, c-12),
CLA has conjugated double bonds with possible cis and/or
trans configurations (Figure 1).
Dietary CLA increased the level of total saturated fatty
acids (mainly C14:0, C16:0 and C18:0) whereas that of
monounsaturated fatty acids (mainly C18:1, n-9) was
decreased (14). The shift toward a higher deposition of
saturated fatty acids and lower deposition of
monounsaturated fatty acids is the result of down
regulation of stearoyl-CoA desaturase activity by t-10, c12 CLA isomer (38). Changes in the body composition,
such as reduced body fat, enhanced body protein, ash and
water were found to be associated with the feeding the t10, c-12 CLA isomer in mice, but not the c-9, t-11 CLA
isomer (39). CLA was shown to alter the fatty acid
composition of milk fat and inhibit milk fat secretion in
dairy cows (40). In this study, the researchers showed
that CLA content (% of fatty acid methyl esters) of milk
fat increased in a dose-dependent manner. They also
reported that CLA infusion into abomasum of cows had
no effect on milk protein, but reduced the content and
yield of milk fat (40). The complete mechanism by which
dietary CLA causes decreased milk fat accumulation is not
known.
Dietary CLA was shown to decrease subcutaneous fat
depot and increase lean body mass in pigs fed a cerealbased diet containing 2% CLA compared to pigs fed
control diet (2% sunflower oil) (41). Also Dugan et al.
(41) reported that dietary CLA tended to improve feed
efficiency in the pigs. Another study conducted in pigs
confirmed those findings shown by Dugan et al. (42).
Studies conducted in dairy cows demonstrated that
abomasal infusion of CLA decreased milk fat yield. Those
effects may be due to CLA isomers containing a t-10
double bond (43). In another study, t-10, c-12 CLA was
shown to result in a curvilinear reduction in milk fat
ranging from 25% with abomasal infusion of 3.5 g/d to
50% with 14.0 g/d (44).
Conjugated linoleic acid (CLA) was shown to reduce
body fat mass (BFM) in animals. To investigate the dose192

response relationships of CLA with regard to BFM in
humans, a randomized, double-blind study including 60
overweight or obese volunteers (body mass index 25–35
kg/m2) was performed (45). The subjects were divided
into five groups receiving placebo (9 g olive oil), 1.7, 3.4,
5.1 or 6.8 g CLA per day for 12 wk, respectively. In that
study conducted in obese humans, CLA was shown to
reduce body fat mass and that no additional effect on
body fat mass was achieved with doses >3.4 g CLA/d
(45). It was also found that the reduction of body fat
within the groups was significant for the 3.4 and 6.8 g
CLA groups (P=0.05 and P=0.02, respectively). No
significant differences among the groups were observed
related to lean body mass, body mass index, blood safety
variables and blood lipids (45).
C. Antiatherogenic Activity of CLA
While considerable research has focused on a potential
anticarcinogenic effect of CLA, there are few studies
indicating that CLA may also reduce the risk of
cardiovascular diseases in animal models (46,47). A study
conducted in rabbits showed that dietary CLA resulted in
a marked decline in the levels of total plasma cholesterol,
triacylglycerol, and the ratio of LDL to HDL cholesterol
(46). In addition, less atherosclerosis was detected in the
aortas of the rabbits fed CLA relative to the control (46).
Similar results on cholesterol metabolism were reported
in hamsters fed CLA. The hamsters fed CLA had lower
levels of total plasma cholesterol, non-HDL cholesterol
(very low and LDL included), and triacylglycerol compared
to control-fed hamsters. An antioxidant effect of CLA was
suggested by determination of plasma tocopherol/total
cholesterol ratios. Similar to the findings by Lee et al.
(46), measurement of the aortic fatty streak areas
revealed less early atherosclerosis in the CLA-fed
hamsters (47).
Recently, a study conducted in hamsters showed that
a mixture of CLA influenced body weight gain and plasma
lipids (48). In this study, the three experimental diets fed
to the hamsters consisted of the mild atherogenic diet
plus CLA mixture at 10g/kg diet (CLA group), c-9, t-11
CLA at 2g/kg diet (c-9, t-11 group) or linoleic acid at
2g/kg diet (LA group). The CLA mixture was reported to
decrease the levels of plasma triacylglycerol, total
cholesterol and non-HDL cholesterol significantly after 2
weeks or 6 weeks of feeding the treatments compared to
the LA group, but not the c-9, t-11 CLA group (48).
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In the literature, dietary CLA has been reported to
have controversial results on atherosclerosis in mice. One
reported that CLA actually did not reduce the incidence of
atherosclerosis, but increased the incidence of fatty acid
streaks in mice compared to control-fed mice (49). The
mice fed CLA had significantly lower concentration of
serum triacylglycerol and a significantly higher ratio of
serum HDL-cholesterol:total cholesterol (49). The
addition of CLA to the atherogenic diet actually was
shown to increase the development of aortic fatty
streaks. This study conducted by Munday et al. (49)
contradicts the finding of studies conducted in rabbits and
hamsters (46,47). It is possible that dietary CLA has
different influences on the fatty acid and cholesterol
metabolism in different animal species. More research is
necessary to elucidate the effects of dietary CLA on lipid
metabolism and atherogenesis in animal models and
eventually human beings.
The consequence of the inhibition of stearoyl-CoA
desaturase by CLA may be relevant to lipoprotein
metabolism (50). The secretion of VLDL from liver
requires synthesis of an apoprotein called apoB-100 and
sufficient amount of oleic acid (C18:1, n-9) (51). CLA was
shown to decrease the levels of plasma triacylglycerol,
VLDL and LDL in rabbits (46). It was also shown that the
synthesis of apoB-100 and secretion of triacylglycerol in
Hep G2 cells were inhibited by CLA (46). C18:1, n-9
stimulated both the synthesis and secretion of VLDL and
apoB-100 in HepG2 and Caco-2 cells (52). The
researchers suggested that increased secretion of apo-B
in response to C18:1(n-9) could be due to increased de
novo synthesis of apo-B (52). Mice fed for 2 weeks either
a fat-free high carbohydrate diet or a 5% corn oil diet,
supplemented with or without 0.5% CLA mixture (42%
c-9, t-11 and 44% t-10, c-12 CLA isomers), had a 45%
and 75% decrease, respectively, in stearoyl-CoA
desaturase mRNA levels in the liver compared to control
(38). Some suggested that CLA could result in a decrease
in VLDL and apoB-100 secretion by inhibiting the
stearoyl-CoA desaturase enzyme activity (50). The t-10,
c-12 CLA isomer significantly reduced apolipoprotein
secretion in the HepG2 cells compared to the linoleic acid
control and the c-9, t-11 CLA isomer (53).

D. Role of CLA in Immune Function
Dietary CLA was shown to prevent immune-induced
growth
suppression
following
endotoxin
(lipopolysaccharide, LPS) injection in chicks and rats (35).
What was observed was that the control fed LPS injected
chicks lost weight over 24 hours, but those fed CLA
continued to grow even though immune stimulated. The
study was repeated in mice and rats showing that CLA
protected against immune stimulation across animal
species (54).

Conclusion
CLA has been shown to have many biological activities
(i.e. anticancer activity, immune-enhancing activity,
weight-reducing effects and possible antiatherogenic
properties) in animals at levels below 1% of the total
energy in the diet (26). Because of those biological
properties of CLA, recently there are a lot of interest in
enriching egg, meat and dairy products for human
consumption. It is possible to change the lipid
composition of food products easily, such as eggs, milk or
meat, by modifying the diet of the animals. Daily intake
of CLA is not well documented, but has been estimated to
be under several hundred mg/d (26). Animal data
indicated that about 3.0 g/d of CLA may be necessary for
beneficial effects in humans (26).
Since CLA is a mixture of several isomers, any isomer
might have different activities or work synergistically.
Currently, the c-9, t-11 CLA and t-10, c-12 CLA are the
only isomers that have actually been shown to exert
physiological properties. It is not known if the other CLA
isomers have biological activities as well. As the individual
CLA isomers become more available, studies have been
conducted to compare the isomers of CLA and find out
physiological activities of certain isomers.
Today, CLA has been studied extensively mainly in
USA, France, Japan, Italy, and Norway. The studies
conducted up to now produced more questions than
answers. Especially the mechanisms how CLA works in
health and disease conditions are not clear. Therefore, it
appears it will take much longer to elucidate the function
of CLA in health and diseases.
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